To hear about similar clinical trials, please enter your email below
Trial Title:
Intratumoral CAN2109 in Subjects With Solid Tumors
NCT ID:
NCT06332430
Condition:
Solid Tumor
Lymphoma
Conditions: Official terms:
Neoplasms
Study type:
Interventional
Study phase:
Phase 1
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
CAN2109
Description:
CAN2109 IT injection (once every 3 weeks)
Arm group label:
CAN2109
Summary:
A phase 1, dose escalation, open-label study of intratumoral CAN2109 in subjects with
unstable or metastatic advanced solid tumors or lymphomas.
Detailed description:
The scope of the study is to evaluate the safety of CAN2109 in humans, explore its
safety, efficacy and collect data on the pharmacokinetics, as well as on the
pharmacodynamic effect of the drug on the immune system locally and systemically, and on
tumor markers.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. Able and willing to provide written informed consent and willing to comply with the
study's requirements.
2. Male or female age ≥ 18 years at screening.
3. Metastatic or locally advanced solid tumor that has progressed on, is refractory to,
or for which there is no efficacious standard of care therapy. Preferred tumor types
include the following:
a. Carcinoma of skin, melanoma, Merkel cell carcinoma (MCC), breast cancer, head and
neck squamous cell carcinoma (HNSCC), sarcoma, cervical carcinoma, and colorectal
cancer
4. Performance status of 0-1 on the ECOG Performance Scale.
Exclusion Criteria:
1. Unresolved toxicities from prior therapy, defined as having not resolved to Common
Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (v5.0) Grade 0 or 1,
with exception of endocrinopathies from prior therapy, alopecia, and vitiligo.
2. Treatment with systemic corticosteroids at doses exceeding 10 mg/day prednisone or
equivalent.
3. Has an active infection requiring systemic therapy.
4. Unstable/inadequate cardiac function defined as follows:
1. New York Heart Association Class 3 or 4 congestive heart failure
2. uncontrolled hypertension
3. acute coronary syndrome within 6 months
4. clinical important cardiac arrhythmia
5. mean corrected QT (QTc) interval corrected for heart rate > 480 ms.
5. A history of interstitial lung disease.
6. A history of coagulopathy resulting in uncontrolled bleeding or other bleeding
disorders.
7. Participated in a clinical study of an investigational agent within 30 days of
screening.
8. Has known psychiatric, substance abuse, or other disorders that would interfere with
cooperation with the requirements of the study in the opinion of the investigator.
9. Is pregnant or breastfeeding.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Sun Yat-Sen University Sun Yat-Sen Memorial Hospital
Address:
City:
Guangzhou
Zip:
510535
Country:
China
Status:
Recruiting
Contact:
Last name:
Herui Yao, Professor
Start date:
May 28, 2024
Completion date:
May 30, 2026
Lead sponsor:
Agency:
Canwell Biotech Limited
Agency class:
Industry
Source:
Canwell Biotech Limited
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06332430